NCT01458392 2022-10-05
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Phase 2 Completed
Clinical Trials
3 trialsNCT01720173 2021-10-20
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 2 Completed
NCT01642082 2018-03-13
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed